Adrenaline

Dry Powder Epinephrine Product Demonstrates Reliable and Consistent Delivery in Real-World Dosing Situations with a Heat-Stable Formulation RALEIGH, NC / ACCESSWIRE / December 11, 2024 / Belhaven Biopharma, a leader in nasal drug delivery and severe allergy treatment, is set to present new research findings on Nasdepi®, its innovative dry powder nasal epinephrine product, at the 35th annual Drug Delivery to the Lungs (DDL) Conference in Edinburgh, Scotland. The presentation, titled "Investigation of the Impact of Particle Size and Patient Factors on the Nasal Deposition of a Life-Saving Epinephrine Product (Nasdepi®)," will take place on Thursday, December 12th, and will highlight Belhaven's latest studies focusing on nasal delivery effectiveness in real-world patient situations and ability to withstand exposure to sustained high temperatures with minimal degradation when compared to liquid formulations.Nasdepi®, a needle-free alternative to traditional epinephrine autoinjectors, addresses common barriers like needle phobia, short shelf life, user error, and accessibility challenges with temperature-sensitive products. Current autoinjectors are often underutilized due to their high cost, limited availability, and patient hesitancy; while their liquid formulations degrade rapidly under extreme environmental conditions. Three new studies by Belhaven focusing on nasal delivery effectiveness and heat stability highlight Nasdepi®'s potential to provide consistent, reliable treatment in real-world situations, independent of patient level of consciousness across diverse climates."These studies further confirm Nasdepi®'s ability to overcome critical shortcomings with current anaphylaxis treatments," said Brian Taubenheim, COO of Belhaven Biopharma, who will present the new research at DDL 2024. "Our focus continues to be on developing products that expand patient access to easy-to-use safe, effective, and dependable treatments that can save lives."Key findings:Effective Nasal Deposition: Nasdepi® demonstrated reliable drug delivery within the nasal cavity, with more than 95% of the dose depositing in the nasal cavity regardless of orientation, nasal coating, or airflow, ensuring minimal lung exposure.Stability in Extreme Conditions: A 12-week study confirmed that Nasdepi® retains over 99% potency, with no chemical or physical degradation, even when exposed to temperatures up to 50°C (122°F).The data supports Nasdepi® as a viable alternative to epinephrine autoinjectors and other liquid formulations, particularly in settings where storage and distribution are challenges. The heat tolerance observed is superior to current liquid nasal and intramuscular treatments which provides potential access for regions that currently have no feasible alternatives outside of a hospital setting. The reliable nasal deposition profile indicates Nasdepi® could be effectively self-administered by patients, or administered by bystanders or healthcare providers, without the concern of positioning or potentially needing a second dose due to a runny nose.The DDL Conference, taking place in Edinburgh, Scotland, attracts over 1,000 global experts annually, including scientists, clinicians, and industry leaders. Belhaven Biopharma will present these findings during Session 4: Advances in Nasal Drug Delivery on December 12, 2024, beginning at 10:20 am GMT.For more information, visit https://ddl-conference.com/.About Belhaven Biopharma:Belhaven Biopharma is a clinical-stage pharmaceutical research company specializing in developing life-saving medications delivered quickly, effectively, and painlessly with a simple, dry powder, single-use nasal device. They are at the forefront of developing nasal dry powder epinephrine, which is revolutionizing emergency-use epinephrine delivery and expanding global access. Nasdepi®, Belhaven's lead program, is the first dry powder nasal device for treating life-threatening allergic reactions.Contact InformationJanie Mackenzie Vice President of Public Relations[email protected]267.969.4992SOURCE: Belhaven Biopharma

Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy® (epinephrine nasal spray) 2mg for use in emergency treatment of allergic reactions including anaphylaxis Interested schools are encouraged to review applicable state laws and regulations to ensure neffy for undesignated use meets all requirements SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that it will be launching the neffyinSchools Program in January 2025. The program will provide eligible public and private K-12 schools in the U.S. the opportunity to receive two cartons (four single use doses) of neffy® (epinephrine nasal spray) 2mg for use in emergency situations at no cost to the school. neffy 2mg was recently approved for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.) Participating schools will be eligible to receive replacement doses when the product is used or expires. Type 1 allergic reactions can be life-threatening, can happen in minutes, and can be caused by stinging and biting insects, foods, medication, exercise, or other unknown causes. Studies show that up to 18% of children with food allergies have had a reaction from accidentally eating food allergens while at school.1 In addition, 25% of severe and potentially life-threatening reactions (anaphylaxis) reported at schools happened in children with no previous diagnosis of food allergy.1 “The potential for severe allergic reactions to food, medication, exercise or insect bites can quickly result in an emergency if epinephrine is not available. Since many unexpected allergic reactions happen during the school day, readily available epinephrine is crucial,” says Richard Lowenthal, Co-Founder, President and CEO of ARS Pharmaceuticals. “Additionally, many people, including students, have a fear of needles which could impact, delay or prevent the use of an auto-injector. We are committed to making neffy, the only needle-free epinephrine treatment option, available free of charge to all eligible schools through our neffyinSchools program because we know neffy will save lives. We also understand that there are currently many challenges for schools that stock epinephrine. neffy is safer for school staff when administering epinephrine in allergy emergency situations, is easier to dispose as neffy doesn’t contain any sharps, and it has a long shelf life of 30 months.” In advance of the neffyinSchools launch, schools are encouraged to review applicable state legislation to ensure neffy meets the requirements of local epinephrine stocking and indemnification laws for undesignated use. Currently, 49 states and Washington DC have legislation in place to allow schools to stock epinephrine. The details of each state’s legislation, and ability to stock neffy specifically, may vary. For states that do not yet allow for neffy because stocking protocols have not been updated to reflect this product and/or route of administration, school administrators may need to contact their state legislator to request modifications to state legislation to ensure school personnel are indemnified from liability for use of FDA approved epinephrine products. Many patient advocacy groups have information and resources on this topic that can be found here. A webinar will be hosted on December 12 to provide information to school nurses and adminstrators about the neffyinSchools program, general information about neffy as well as training and other online resources. Following the program’s official launch in January 2025, ARS Pharma will provide application instructions to schools to receive neffy 2mg. More information about this program can be found at www.ars-pharma.com and www.neffy.com under the Community Program tab. Additional updates will be provided on ARS LinkedIn and X pages. The neffyinSchools program is subject to the more detailed terms and conditions which will be available on the Company’s website prior to the official launch of the neffyinSchools program. About neffyinSchools ARS is committed to working with our communities to provide essential epinephrine in schools. Eligible public and private K-12 schools in the U.S. (excluding territories) will be able to receive two cartons (four single use doses) of neffy 2mg for adults and children who weigh ≥30 kg (66 lbs.), in emergency situations. The neffyinSchools program is only for undesignated use, and children with prescriptions for epinephrine from their healthcare provider must continue to supply medication to their school in accordance with school guidelines. Schools must review applicable state legislation to ensure neffy meets the requirements of local epinephrine stocking and administration laws for undesignated use. The supplemental NDA for neffy 1mg dose was granted priority review by the FDA and has a PDUFA date set for March 6, 2025. If approved, neffy 1mg will be available to schools for students who weigh between 33 and 66 lbs. The neffyinSchools program is subject to the more detailed terms and conditions which will be available on the Company’s website prior to the official launch of the neffyinSchools program About neffy® neffy is an intranasal epinephrine product for patients with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis. INDICATION AND IMPORTANT SAFETY INFORMATION FOR neffy (epinephrine nasal spray) INDICATION neffy 2 mg is indicated for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater. IMPORTANT SAFETY INFORMATION It is recommended that patients are prescribed and have immediate access to two neffy nasal sprays at all times. In the absence of clinical improvement or if symptoms worsen after initial treatment, administer a second dose of neffy in the same nostril with a new nasal spray starting 5 minutes after the first dose. neffy is for use in the nose only. Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required. Absorption of neffy may be affected by underlying structural or anatomical nasal conditions. Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris or produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics. The presence of a sulfite in neffy should not deter use. neffy may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including neffy. Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson’s disease, diabetes, renal impairment. Epinephrine should be administered with caution in patients with these conditions, including elderly patients and pregnant women. Adverse reactions to neffy may include throat irritation, intranasal paresthesia, headache, nasal discomfort, feeling jittery, paresthesia, fatigue, tremor, rhinorrhea, nasal pruritus, sneezing, abdominal pain, gingival pain, hypoesthesia oral, nasal congestion, dizziness, nausea, and vomiting. These are not all of the possible side effects of neffy. To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For additional information on neffy, please see Full Prescribing Information at www.neffy.com. About Type I Allergic Reactions Including Anaphylaxis Type I allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine autoinjectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 40 million people in the United States who experience Type I allergic reactions. Of this group, over the last three years, approximately 20 million people have been diagnosed and treated for severe Type I allergic reactions that may lead to anaphylaxis, but (in 2023, for example) only 3.2 million filled their active epinephrine autoinjector prescription, and of those, only half consistently carry their prescribed autoinjector. Even if patients or caregivers carry an autoinjector, more than half either delay or do not administer the device when needed in an emergency. About ARS Pharmaceuticals, Inc. ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® 2 mg (trade name EURneffy® in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com. Forward-Looking Statements Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: the expected timing and launch of neffyinSchools; the needle-free profile of neffy and making neffy available at no cost to eligible public and private K-12 schools increasing the likelihood that such schools will both carry and administer adrenaline to students experiencing an allergic reaction; the expectation that neffy will save lives; the potential for stocking neffy to qualify under indemnification laws for undesignated use; and other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate,” “expects,” “if,” “may,” “potential,” “on track to,” “plans,” “will,” “would,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon ARS Pharmaceuticals’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: potential safety and other complications from neffy; ARS Pharmaceuticals may not receive the anticipated benefits from the neffyinSchools program; public and private schools may be participate in the neffyinSchools program to the degree or on the timelines expected by ARS Pharmaceuticals the scope, progress and expansion of developing and commercializing neffy; the potential for payors to delay, limit or deny coverage for neffy; the size and growth of the market therefor and the rate and degree of market acceptance thereof vis-à-vis intramuscular injectable products; ARS Pharmaceuticals’ ability to protect its intellectual property position; the impact of government laws and regulations; and the PDUFA target action date may be delayed due to various factors outside ARS Pharmaceuticals’ control. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” in ARS Pharmaceuticals’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange Commission (“SEC”) on November 13, 2024. These documents can also be accessed on ARS Pharmaceuticals’ website at www.ars-pharma.com by clicking on the link “Financials & Filings” under the “Investors & Media” tab. The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharmaceuticals assumes no obligation and does not intend to update these forward-looking statements, except as required by law. ARS Investor Contact:Justin ChakmaARS Pharmaceuticalsjustinc@ars-pharma.com ARS Media Contact:Christy CurranSam Brown Inc.615.414.8668christycurran@sambrown.com 1 Centers for Disease Control and Prevention. Voluntary Guidelines for Managing Food Allergies in Schools and Early Care and Education Programs. Washington, DC: US Department of Health and Human Services; 2013.